netupitant has been researched along with Sarcoma* in 1 studies
1 other study(ies) available for netupitant and Sarcoma
Article | Year |
---|---|
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients.
Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared and disturbing adverse events of cancer treatment associated with decreased adherence to effective chemotherapy regimens. For high-risk soft tissue sarcoma patients, receiving multiple-day chemotherapy (MD-CT), antiemetic guidelines recommend a combination of an NK. We performed a prospective, non-comparative study to assess the efficacy of one shot of NEPA plus dexamethasone in sarcoma patients receiving MD-CT. The primary efficacy endpoint was a complete response (CR: no emesis, no rescue medication) during the overall phase (0-120 h) in cycle 1. The main secondary endpoints were CR during the overall phase of cycles 2 and 3.. The primary endpoint was reached in 88.9% of patients. Cycles 2 and 3 overall CR rates were 88.9% and 82.4%, respectively. The antiemetic regimen was well tolerated.. This pilot study showed the benefit of one shot of NEPA to prevent CINV in sarcoma patients receiving MD-chemotherapy. Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Pilot Projects; Prospective Studies; Pyridines; Quinuclidines; Receptors, Neurokinin-1; Sarcoma; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2019 |